SCHOOL OF MEDICINE  |  PITT HOME  |  FIND PEOPLE  |  FIND A DOCTOR AT UPMC

Department of Medicine

Department of Medicine

  Division of Pulmonary, Allergy and Critical Care Medicine



[Return To Index page]
photo Stevan P. Tofovic, MD, PHD, FAHA, FASN

Associate Professor of Medicine

Email: tofovic@pitt.edu

Phone: 412-648-3363

Contact
Office: 542 Bridgeside Point I Building
100 technology Drive
Pittsburgh, PA 15219
 
Phone: 412-648-3363
Fax: 412-648-5070
E-mail: tofovic@pitt.edu
Administrative Assistant:
Judy Nauman
Email: naumanja@upmc.edu
Phone: 412-864-3199
Fax: 412-692-2210
Education and Training
Education
MD, University of Skopje School of Medicine, Republic of Macedonia, 1979
MS, Pharmacology, University of Skopje School of Medicine, Republic of Macedonia, 1984
PhD, Pharmacology, University of Skopje School of Medicine, Republic of Macedonia, 1992
Training
Recidency in Medicine - General Practitioner, University of Skopje Medical Center, School of Medicine, Skopje, Republic of Macedonia, 1980
Recidency in Medicine and Clinical Pharmacology, University of Skopje Medical Center, School of Medicine, Skopje, Republic of Macedonia, 1982
Postdoctoral Fellowship in Clinical Pharmacology, Vanderbilt University School of Medicine, 1989
Research Interest
Dr. Tofovic has had a sustained interest in the development and characterization of complex animal models of cardiovascular and renal disease, with primary focus on pulmonary hypertension, heart failure and diabetic nephropathy. Using these model systems, he studies the underlining pathophysiology of cardiovascular/renal diseases and evaluates new therapeutic modalities. Dr. Tofovic has developed and characterized the obese diabetic ZSF1 rat as a model of diabetic nephropathy and heart failure with preserved ejection fraction (HFpEF)and has published most of the papers in this area.

Dr. Tofovic’s lab is one of the few laboratories in the country that is studying the effects of gender and estradiol metabolism on the development and progression of pulmonary hypertension. He was first to suggest that estradiol metabolism may influence the development and progression of PH (2005). More recent studies are related to (1) the effects of sex and sex hormones and their metabolites on development of HFpEF and (2) the role of adenosine metabolom and adenosine-adenosine demainase axis in PH with focus on hemolysis-induced hemolytic pulmonary vasculopathy
Educational Interest
In 1996, Dr. Tofovic developed and for twenty years has served as course director for the Selective in Clinical Pharmacology course for senior medical students. His interest in teaching medical students rational drug prescribing and therapeutics includes several innovative approaches: the “One-day PBL in Therapeutics” format; the “Personal Formulary” concept for drug selection;and development of the “Evidence Based Pharmacotherapy“ block with workshops on Critical Appraisal of Literature on Therapeutics, Drug Promotion and Medical Controversies. The content and teaching modalities used for this course largely mirror recent recommendations of the Association of American Medical Colleges on Education in Safe and Effective Prescribing (Report X, 2008). Dr. Tofovic is longest serving course director at University of Pittsburgh School of Medicine and one of the first 50 faculty to be appointed to the Academy of Master Educators in the School of Medicine.
Publications
For my complete bibliography, Click Here.
Selected Publications:
Tofovic, SP, Salah, EM, Smits, GJ, Whalley, ET, Ticho, B, Deykin Jackson, EK. Dual A1/A2B Receptor Blockade Improves Cardiac and Renal Outcomes in a Model of Heart Failure with Preserved Ejection Fraction. J Pharmacol Exp Ther. 2016; 356(2): 333-40.
Lai, YC, Tabima, DM, Dube, JJ, Hughan, KS, Goncharov, DA, Vanderpool, RR, St. Croix, CM, Garcia-Ocana, A, Goncharova, EA, Tofovic, SP, Mora, AL, Gladwin, MT. SIRT3-AMPK Activation by Nitrite and Metformin Improves Hyperglycemia and Normalizes Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF). Circulation. 2016; 133(8): 717-731.
Rafikova, O, Rafikov, R, Kumar, S, Sharma, S, Aggarwal, S, Schneider, F, Jonigk, D, Black, S, Tofovic, SP. Bosentan inhibits oxidative and nitrosative stress and rescues occlusive pulmonary hypertension. Free Radic Biol Med. 2013; 56: 28-43.
Bilan, VP, Salah, E, Bastacky, SI, Jones, H, Rachel, M, Zinker, B, Poucher, S, Tofovic, SP. Renal, cardiovascular, and metabolic effects of rosiglitazone and enalapril in obese, diabetic, hypertensive, ZSF1 rats. J Endocrinology. 2011; 210: 1-16.
Tofovic, SP. Estrogens and development of pulmonary hypertension - Interaction of estradiol metabolism and pulmonary vascular disease. J Cardiovasc Pharmacol. 2010; 56(6): 696-708.
Tofovic, SP, Jones, TJ, Bilan, V, Jackson, EK, Petrusevska, G. Synergistic effects of 2-methoxyestardiol with either sildenafil or bosentan on amelioration of monocrotaline-induced pulmonary hypertension and vascular remodeling. J. Cardiovasc Pharmacol. 2010; 56(5): 475-483.
Tofovic, SP, Jackson, EK, Rafikova, O. Adenosine Deaminase-Adenosine pathway in hemolysis–associated pulmonary hypertension. Medical Hypotheses. 2009; 72: 713-719.
Tofovic, SP, Zhang, X, Jackson, EK, Dacic, S, Petrusevska, G. 2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension. Vascular Pharmacology. 2006; 45: 358-367.
Tofovic, SP, Eman, S, Mady, H, Jackson, EK, Melhem, M. Estradiol metabolites attenuates monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol. 2005; 46: 430-437.
Sponsored Research/Activities
Title: Effects of Dual (ETA/ETB) Versus Single (ETA) Endothelin Receptor Inhibition on Naphthylthiourea (ANTU) - Induced Vascular Leakage and Pulmonary Hypertension
Role: Principal Investigator
Funding Agency: Actelion Clinical Operations
Start Year: 2015
End Year: 2020
Title: Evaluate Whether Suprarenal Abdominal Aorta Constriction (SRAAC) in ZSF-1 Rats Can Serve as an Animal Model for Heart Failure with Preserved Ejection Fraction (HFpEF)
Role: Principal Investigator
Funding Agency: Merck
Grant Number: DRUG
Start Year: 2015
End Year: 2016
Title: Role of Cardiac and Renal DPPP4
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL069846
Start Year: 2017
End Year: 2021
Title: RV/PA Recoupling by Bone Marrow Derived Mesenchymal Stem Cells
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL114795
Start Year: 2012
End Year: 2017
Title: Role of Renal Dipeptidyl Peptidase IV
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL069846
Start Year: 2012
End Year: 2017
Title: The Renal 2',3'-cAMP-Adenosine Pathway
Role: Co-Investigator
Funding Agency: National Institute of Diabetes, Digestive, & Kidney Disease
Grant Number: R01 DK068575
Start Year: 2012
End Year: 2017
Title: The Guanosine-Adenosine Mechanism
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL109002
Start Year: 2012
End Year: 2016
Notable Achievements
Recipient of the Macedonian Ministry of Science Annual Scholarship Awards for Highest Scholastic Achievement, 1978
NIH Fogarty Postdoctoral Fellowship Award for Advanced Study in Health Sciences, 1989
Recipient of the Kenneth Schuit Award, University of Pittsburgh School of Medicine Dean’s Award for Master Educator for Outstanding Achievements in Educating Physicians in Two Thousand, 2000
Fellow, American Heart Association (FAHA), 2003
Fellow, American Society of Nephrology (FASN), 2004
Member of the Academy of Master Educators, University of Pittsburgh School of Medicine, 2006
Travel Award by NIH for Excellence in Research in Pulmonary Hypertension, 2006
Science Award, for outstanding scientific research, Pittsburgh International Lung Conference, 2009